01Overview 02Daily Brief 03Live 04Congress 05Corporate Insiders 06Government Money 07Political Influence 08Institutions 09Washington Network 10Follow the Power 11Disclosure Clock 12AI Investigator 13Watchlist

Convergence INSIDER Alpha Signal ledger Historical Replay Robinhood Chain Proof Trading Token Methodology Match review Launch readiness

Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…

Overview Daily Brief Live Congress Corporate Insiders Government Money Political Influence Institutions Washington Network Follow the Power Disclosure Clock AI Investigator Watchlist Convergence INSIDER Alpha Signal ledger Historical Replay Robinhood Chain Proof Trading Token Methodology Match review Launch readiness

01Overview 02Daily Brief 03Live 04Congress 05Corporate Insiders 06Government Money 07Political Influence 08Institutions 09Washington Network 10Follow the Power 11Disclosure Clock 12AI Investigator 13Watchlist

Convergence INSIDER Alpha Signal ledger Historical Replay Robinhood Chain Proof Trading Token Methodology Match review Launch readiness

Overview Daily Brief Live Congress Corporate Insiders Government Money Political Influence Institutions Washington Network Follow the Power Disclosure Clock AI Investigator Watchlist Convergence INSIDER Alpha Signal ledger Historical Replay Robinhood Chain Proof Trading Token Methodology Match review Launch readiness

Data sources

SEC FORM 45h ago

HOUSE PTR5h ago

SEC 13F5h ago

ROBINHOOD CHAIN5h ago

Public company

IVVDInvivyd, Inc.

CIK 0001832038

EDGAR filings Open in network

Disclosed transactions0

Buys / sells0 / 0

Max Insider Score—

Connections3with evidence

IVVD · disclosed activity on price

Disclosed transactions

No records

No transactions recorded for this profile.

Verified connections

In industryevidence
Pharmaceuticals, devices & health servicesSEC SIC 2836 · Biological Products, (No Diagnostic Substances) · Nov 4, 2026
← Lobbied forevidence
FORBES-TATELDA Q1 2026 first quarter · Health issues · Aug 26, 2026
← Lobbied forevidence
KING & SPALDING LLPLDA 2TY 2026 second quarter · issues not listed · Aug 26, 2026

Lobbying

$80K reported · de-duplicated

2026 Q2 $60K in-house2026 Q1 $20K in-house

FORBES-TATE$120K2026 Q2 · posted Aug 26, 2026 · Health issues
KING & SPALDING LLP—2026 Q1 · posted Aug 26, 2026 · Health issues, MAN
KING & SPALDING LLP—2026 Q1 · posted Aug 26, 2026 ·
In-house report$20K2026 Q1 · posted Aug 26, 2026 ·
FORBES-TATE$60K2026 Q1 · posted Aug 26, 2026 · Health issues
KING & SPALDING LLP—2026 Q2 · posted Aug 26, 2026 ·
In-house report$60K2026 Q2 · posted Aug 26, 2026 · MAN, Health issues

Connected PAC contributions

FEC · direct to members

No contributions from a PAC connected to this company.